Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

White House scraps proposal to lower U.S. drug prices

The Trump administration scrapped a proposal for lowering prescription medicine prices, backing down from a policy that would have required health insurers to pass on billions of dollars in rebates they receive from drugmakers to Medicare patients.

Read More »

U.S. appeals court signals sympathy to bid to strike down Obamacare

A federal appeals court panel expressed skepticism to Democratic calls to overturn the ruling of a Texas judge who found the landmark U.S. healthcare reform law unconstitutional.

Read More »

U.S. Supreme Court takes up insurers’ $12 billion Obamacare dispute

The U.S. Supreme Court agreed to decide whether the federal government must pay insurers $12 billion under an Obamacare program aimed at encouraging them to cover previously uninsured people after the healthcare law was enacted in 2010.

Read More »

Trump to issue executive order seeking transparency on healthcare costs: Wall Street Journal

U.S. President Donald Trump plans to issue an executive order asking health insurers and doctors to disclose new details about healthcare costs in an attempt to improve price transparency, the Wall Street Journal reported, citing people familiar with the matter.

Read More »

UnitedHealth gets FTC approval for DaVita unit purchase

UnitedHealth Group Inc. won anti-trust approval to buy DaVita Inc.’s primary and urgent care unit for $4.3 billion, the Federal Trade Commission said.

Read More »

The Rebate System Spikes Drug Prices, Scripps Study Confirms

As concerns over the price of prescription medicine continue to make headlines as the country barrels toward another election, a new study from the Scripps Research bolsters an argument touted by the pharmaceutical industry over the rebate system.

Read More »

Lilly’s new migraine drug pulls ahead of Amgen in fierce battle for new prescriptions

Eli Lilly and Co. pulled ahead in a three-way race with Amgen Inc. and Teva Pharmaceutical Industries Ltd. in attracting new patients to a new class of migraine drugs, and seeks to build on that advantage by stressing that the company’s therapy can completely prevent headaches in a small percentage of patients.

Read More »

The obscure advisory committees at the heart of the U.S. drug pricing debate

Expectations were high during 2018 for three new migraine drugs hitting the market from Amgen Inc., Eli Lilly and Co. and Teva Pharmaceutical Industries Ltd. Priced around $7,000 each, the drugmakers called them “breakthrough” treatments designed to prevent migraines when taken year-round, and estimated that millions of patients could benefit. But a small group of medical experts who quietly advise U.S. health insurers on new drugs was not impressed, according to a private meeting held at UnitedHealth Group’s OptumRx offices in Chicago that was attended by Reuters.

Read More »

With a Pharma Market Free of Rebates, We Can Sell on Value Again

The pharmaceutical industry’s greatest value lies in the quality of life that its drugs provide – plus the innovative programs that help support adherence and education.

Read More »

China’s Ant Financial amasses 50 million users, mostly low-income, in new health plan

A mutual health aid plan launched by Ant Financial Services Group – the dominant fintech player in China – has amassed more than 50 million users and is aiming for 300 million within two years, the company said.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!

Subscribe

Ad Right Bottom